Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01299337 · ClinicalTrials.gov registry record
Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)
A clinical trial of Depression, sponsored by Mayo Clinic.
- Completed
- Registry status
- 29
- Enrollment target
- 1
- Study location
NCT01299337: Completed study of Depression, sponsored by Mayo Clinic.
NCT01299337 is a study of Depression that has completed, run by Mayo Clinic. The registered enrollment target is 29 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01299337, a study of Depression, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is: * To evaluate liothyronine (Cytomel) as an accelerating agent (i.e. faster rate to clinical remission) to electroconvulsive therapy. * To evaluate whether thyroid supplement acceleration can reduce the neurocognitive side effect of ECT treatment. * To evaluate whether thyroid status at the time of remission is associated with subsequent relapse rate. * To evaluate genetic polymorphisms in enzymes responsible for thyroid metabolism and the serotonin transporter promoter gene in depression (5-HTTLRP).
Conditions Studied
Interventions
- DRUG T3
Study Locations (1)
Minnesota
- Mayo Clinic Department of Psychiatry and Psychology - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01299337
The ClinicalTrials.gov registry entry for NCT01299337 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which T3 is the first listed.
NCT01299337 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01299337 about?
NCT01299337 is a clinical study titled "Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)". The purpose of this study is: * To evaluate liothyronine (Cytomel) as an accelerating agent (i.e. faster rate to clinical remission) to electroconvulsive therapy. * To evaluate whether thyroid supplement acceleration can reduce the neurocognitive side effect of ECT treatment. * To evaluate whether ...
What is the current status of trial NCT01299337?
This trial is currently completed. The enrollment target is 29 participants. The study started on 2008-06. Estimated completion is 2012-04.
What conditions does trial NCT01299337 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT01299337?
The interventions under investigation include: T3 (DRUG).
Who is sponsoring clinical trial NCT01299337?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01299337 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Depression and Driving
RECRUITING
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.